Navigation Links
Australian Business Mogul Bruce Mathieson Invests in iSonea

MELBOURNE, Australia and SEVERNA PARK, Md., Aug. 31, 2012 /PRNewswire/ -- Medical technology company iSonea Ltd (ASX: ISN; OTCQX: ISOAD) has raised $1.05 million via a private placement of shares to Investment Holdings Pty Ltd, an entity owned and controlled by prominent Australian businessman Bruce Mathieson.

(Logo: )

The share placement means Mathieson is now a cornerstone investor of the company, with a 15 percent ownership position. The placement covers the company's entire 15 percent issuance capacity and will be followed by an entitlement issue to all shareholders.

Announcing the placement, iSonea Chief Executive Officer Michael Thomas said the investment recognizes the pioneering nature of iSonea's asthma and acoustic respiratory monitoring (ARM™) technologies, as the company sets itself to lead in the global explosion of mobile health disease management.

Thomas continued: "iSonea is committed to developing innovative, non-invasive devices and mobile health applications to improve the management of chronic and costly respiratory disorders such as asthma and COPD.  After the successful launch of our AsthmaSense™ mobile smartphone app this summer, the company is now focused on integrating our existing proprietary ARM sensors and analytical software with the AsthmaSense mobile smartphone app to develop an app based wheeze monitor known as AirSonea™."

AirSonea will run on smartphone (iPhone and Android) platforms, enabling anyone, anywhere, at any time to conveniently monitor asthma events and take appropriate action to control the condition.

Mathieson has held a passionate interest in the IT revolution and the impact of mobile technology on the future of healthcare.  He was attracted to the iSonea business model, leadership team and the company's strong patent position in the respiratory device space.He commented: "iSonea is strongly positioned in the new area of digital health. The asthma monitoring device they are developing to operate with smart phones has enormous potential to help asthmatics worldwide and generate impressive recurring revenue."

"As the late Steve Jobs said in 2010, 'one of the biggest innovations of the 21st Century will be the intersection of biology and technology.  A new era is beginning, just like the digital one when I was my son's age.'  I believe iSonea's products are ahead of the curve and representative of the future of health management."

iSonea's Chairman Dr. Stewart Washer commented: "We welcome Bruce's vision and investment as an opportunity to pioneer the development of innovative digital health technologies which promise to change the way millions of asthma sufferers around the world can manage their conditions."

Mathieson is a respected member of the Australian business community, having built the Bruce Mathieson Group into a significant operation in the hospitality industry.  A joint venture with Woolworths led to the establishment of Australian Leisure and Hospitality Group Pty Ltd (The ALH Group).  Mathieson is a director and holds a 25 percent stake in ALH Group, having previously served as chief executive officer.  Successfully operating in the hospitality and leisure industry since 1974, Mathieson has management experience across several industries and is currently a non-executive director of Mayne Pharma Group Ltd. He is also owner/director of Payment Network International (PNI).  He has served as a director of the Carlton Football Club.

Patersons Securities acted as lead manager to the placement. The placement will be followed by an entitlement issue to all shareholders.  Details of the entitlement issue will follow. Mathieson also intends to participate in the entitlement issue.  Media Inquiries:Michael ThomasHelen Shik or Jen NetzbandChief Executive OfficerSchwartz MSL BostoniSonea Limited+1 781-684-077+1  mthomas@iSoneaMed.comwww.schwartzmsl.comWebsites:,

About iSonea Limited
iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smart phones into medical devices--enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.

For more information, please visit

Forward Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

SOURCE iSonea Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
2. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
3. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
4. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
5. Human Circuit Recognized as an Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2012
6. Organovo Reports Q2 2012 Financial Results, Provides Business Update
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
8. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
9. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
10. AspenBio Pharma to Provide Shareholders with Business Update
11. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
Post Your Comments:
(Date:11/30/2015)... KIRKLAND, Wash. , Nov. 30, 2015 /PRNewswire/ ... of Post-Processing services, is pleased to announce a ... of medical imaging services. Building on its ISO-9001:2008 ... adopted and implemented comprehensive Core Lab protocols and ... wide variety of research activities.  Their Core Lab ...
(Date:11/30/2015)... 30, 2015 Mexico Healthcare and Life Sciences ... Report 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million ... of over 122 million people. --> It offers companies, ... life sciences insights into the second largest pharma and healthcare market ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... The Foundation for Breast and Prostate Health (FBPH)—a ... with the award-winning creator and writer of Downton Abbey Julian Fellowes to host ... Union League of Philadelphia. , The benefit, titled “An Evening with Julian ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a ... today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population ... was awarded the largest Affordable Care Act grant for Federally Qualified Health Centers ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy ... a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the ... and treatment of glaucoma and cataracts, and how a visit with his grandmother to ...
Breaking Medicine News(10 mins):